Hydroxyurea: Mechanisms of HIV-1 inhibition

Antiviral Therapy

Volumn 3, Issue SUPPL. 4, 1998, Pages 25-33

  Lori, Franco ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOSTATIC AGENT; DEOXYADENOSINE TRIPHOSPHATE; DIDANOSINE; HYDROXYUREA; PARATHION; PYRIMIDINE; RIBONUCLEOTIDE REDUCTASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS DNA;

CLINICAL TRIAL; CONFERENCE PAPER; DNA SYNTHESIS INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; PHOSPHORYLATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION; VIRUS INHIBITION;

DEOXYRIBONUCLEOTIDES; HIV-1; HYDROXYUREA; REVERSE TRANSCRIPTASE INHIBITORS; RIBONUCLEOTIDE REDUCTASES; T-LYMPHOCYTES;

EID: 0031797537     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (7)

1. Donehower RC. An overview of the clinical experience with hydroxyurea. Seminars in Oncology 1992; 19 (Supplement 9):11-19.
2. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP & Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. New England Journal of Medicine 1995; 332:1317-1322.
3. Gao W-Y, Cara A, Gallo RC & Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences, USA 1993; 90:8925-8928.
4. Lori F & Gallo RC. Hydroxyurea and AIDS: an old drug finds a new application? AIDS Research and Human Retroviruses 1995; 11:1149-1151.
5. Lori F, Malykh A, Cara A, Sun D, Weinstein JN, Lisziewicz J & Gallo RC. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-805.
6. Lisziewicz J, Jessen H, Finzi D, Siciliano RF & Lori F. HIV-1 suppression by early treatment with hydroxyurea, didanosine, and a protease inhibitor. Lancet 1998; 352:199-200.
7. Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L, Padrini D, Degli Antoni A, Barchi E, Jessen H, Wainberg MA, Gallo RC & Lisziewicz J. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Research and Human Retroviruses 1997; 13:1403-1409.